Pale Fire Capital SE lessened its holdings in shares of Fractyl Health, Inc. (NASDAQ:GUTS – Free Report) by 15.5% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,003,237 shares of the company’s stock after selling 917,808 shares during the quarter. Fractyl Health accounts for about 0.1% of Pale Fire Capital SE’s investment portfolio, making the stock its 27th largest holding. Pale Fire Capital SE owned approximately 3.14% of Fractyl Health worth $3,975,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Nantahala Capital Management LLC bought a new position in shares of Fractyl Health during the third quarter valued at approximately $19,298,000. 683 Capital Management LLC grew its stake in shares of Fractyl Health by 30.1% in the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock valued at $13,305,000 after buying an additional 1,397,620 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Fractyl Health in the 2nd quarter valued at approximately $4,791,000. Marshall Wace LLP increased its position in Fractyl Health by 234.9% in the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock worth $13,039,000 after buying an additional 4,156,969 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Fractyl Health in the third quarter valued at $8,981,000.
Trending Headlines about Fractyl Health
Here are the key news stories impacting Fractyl Health this week:
- Positive Sentiment: Fractyl’s virtual commercial strategy discussion focused on the potential commercialization of its investigational post-GLP-1 procedural therapy. Investor interest ahead of the event briefly supported the shares, but the therapy remains investigational and commercialization depends on future clinical and regulatory progress. Commercial Strategy Day Transcript
- Neutral Sentiment: Multiple law firms reminded investors that October 20, 2026 is the deadline to seek appointment as lead plaintiff in the filed federal securities class action. These announcements are largely investor-solicitation notices and do not establish liability. Faruqi Investor Deadline Notice Bernstein Liebhard Shareholder Alert
- Negative Sentiment: The lawsuit alleges that Fractyl’s SEC filings failed to adequately disclose operational problems at a REMAIN-1 clinical site and used generic risk language. The complaints contend that an “outlier” site skewed Revita DMR weight-maintenance results, while the company promoted those results for roughly a year before disclosing the issue; the notices cite a subsequent 74.86% share-price decline. If proven, the allegations could create litigation costs, reputational damage and questions about the reliability of Fractyl’s clinical data. Levi and Korsinsky Shareholder Alert SueWallSt Class Action Notice
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on GUTS
Insider Transactions at Fractyl Health
In other news, Director William Bradley bought 68,493 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the transaction, the director owned 84,622 shares of the company’s stock, valued at $61,774.06. This represents a 424.66% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ian Sheffield purchased 35,000 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were purchased at an average cost of $0.73 per share, with a total value of $25,550.00. Following the acquisition, the director owned 35,000 shares in the company, valued at $25,550. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 171,493 shares of company stock worth $127,150 over the last quarter. Corporate insiders own 8.36% of the company’s stock.
Fractyl Health Trading Down 0.2%
Shares of GUTS stock opened at $0.71 on Thursday. The stock has a market cap of $112.49 million, a P/E ratio of -0.80 and a beta of 2.34. Fractyl Health, Inc. has a 1 year low of $0.38 and a 1 year high of $2.44. The company has a current ratio of 3.15, a quick ratio of 3.15 and a debt-to-equity ratio of 1.41. The stock has a 50 day simple moving average of $0.74 and a 200 day simple moving average of $0.66.
Fractyl Health (NASDAQ:GUTS – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. On average, research analysts predict that Fractyl Health, Inc. will post -0.53 earnings per share for the current fiscal year.
Fractyl Health Company Profile
Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.
The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.
Read More
- Five stocks we like better than Fractyl Health
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
